• HealthLynked CEO Dr. Michael Dent recently provided $1 million in financing to the company, expected to accelerate its growth and expand its offerings
• Under Dr. Dent’s leadership, the company has developed an expansive array of products and services, including a comprehensive healthcare platform that connects patients, healthcare providers, and medical facilities in a secure, more efficient and cost-effective manner
• The company’s services include online medical records storage, online appointment scheduling for doctors nationwide, telemedicine, patient engagement tools, an e-commerce platform for over 15,000 name-brand medical supplies, concierge patient support, nurse chat, a reward points program, and co-management of family members’ healthcare
• According to Dr. Dent, the financing underscores his belief in the transformative power of HealthLynked’s services and its mission to create a more efficient healthcare system for the benefit of everyone

HealthLynked (OTCQB: HLYK), a Naples, Florida-based leader in personalized healthcare and patient-centric services, leverages technology to provide innovative solutions to healthcare problems, ensuring more efficient, accessible, and personalized healthcare for all. At the heart of the company’s mission is an unwavering determination to transform healthcare on a global scale with the aim of improving the medical practice efficiency and, as a result, increasing the reach of high-quality healthcare services and ensuring more accurate medical diagnosis (https://ibn.fm/uD0Ww).

“The current healthcare system is fragmented and inefficient, often leaving patients frustrated and underserved. At HealthLynked, we are pioneering a new era of healthcare that prioritizes seamless connectivity, personalized care, and data-driven insights,” explained Dr. Michael Dent, CEO of HealthLynked, in a June 5 news release.

The company’s founder and a visionary in the healthcare industry, Dr. Dent has led HealthLynked in developing an expansive array of innovative products and services. Among them is the company’s comprehensive healthcare platform, the HealthLynked Network System, that securely, efficiently, and cost-effectively connects patients, healthcare providers, and medical facilities.

The platform supports a range of services, including online medical records storage, online appointment scheduling for doctors nationwide, telemedicine, and patient engagement tools. According to the company, the healthcare platform aims to improve patient outcomes and increase efficiency throughout the healthcare system (https://ibn.fm/dytnu). In addition to its platform’s offerings, HealthLynked offers additional services: an e-commerce platform for over 15,000 name-brand medical supplies, concierge patient support, nurse chat, a reward points program, and co-management of family members’ healthcare.

To ensure that more patients and healthcare providers can benefit from these innovative solutions and services, HealthLynked recently received $1 million in financing from its CEO Dr. Dent (https://ibn.fm/bME0G). According to the June 5 announcement, the financing is expected to provide HealthLynked with an additional capital runway for accelerating its growth and expanding its offerings further.

“Providing funding to HealthLynked is a testament to my belief in the transformative power of our services and our mission to create a more efficient healthcare system for the benefit of everyone,” commented Dr. Dent. “This financing is not just about financial growth; it’s about leading the way to a more efficient healthcare system of the future, protecting our shareholders’ interests, and assisting our continued success in revolutionizing the healthcare industry.”

Dave Rosal, CFO of HealthLynked, believes this funding will allow the company to “enhance our service offerings and reach more patients and healthcare providers, ultimately driving shareholder value and solidifying our market position in the market.” He also notes that the financing demonstrates Dr. Dent’s commitment to the company, which, in turn, spotlights the strength of its business model and confidence in its strategic direction.

HealthLynked believes this new financing sets it on a path for even greater success and impact in the healthcare sector. It also boosts the company’s efforts to continue to innovate and expand its reach, providing vital healthcare solutions that cater to the needs of patients and healthcare providers.

For more information, visit the company’s website at www.HealthLynked.com.

NOTE TO INVESTORS: The latest news and updates relating to HLYK are available in the company’s newsroom at https://ibn.fm/HLYK

Mining professionals, enthusiasts, businesses, traders, vendors, and investors, are invited to attend the Mining Disrupt Bitcoin Mining Conference (the world’s largest) on June 24-26, 2024, at the Miami Airport Convention Center in Miami. Mining Disrupt has been serving the Bitcoin Mining Industry for years, and their conferences attract attendees worldwide, offering critical education and networking at a global scale.

Bitcoin mining professionals will showcase their latest equipment, hardware, products, and services at the Expo. The event offers a larger-than-life platform for mining enthusiasts, newcomers, and startups, to make the world aware of their unique offerings and get viable investors and businesses. Investors looking for lucrative business ideas can explore the exhibitor booths to discover unique and interesting ideas and products on display.

There are three different categories of passes. The general pass includes access to keynote sessions where industry veterans share their invaluable insights and strategies for the future ahead. Attendees can also access the expo, the Bitcoin Mining Museum, the opening party, the after parties, and a plethora of snacks and breakfast. The VIP pass has some more privileges along with the General pass offerings. The Whale pass has access to all general pass and VIP privileges, along with many more amenities such as the Whale Areas which include Premium Buffet Style Free Foods, Deserts & Premium Drinks.

Sponsorship packages supporting both exhibiting and non-exhibiting brands are available. The organizing team at Mining Disrupt offers adequate coverage to the sponsors and ensures that they enjoy maximum return on investment.

Exhibitors can avail the Booth Design Package option where they can design their own booths.

To learn more, please visit https://ibn.fm/OS8B3.

Proof Of Talk by Xventures invites C-level executives, professionals, and members of the Web3 community, allied industries, and economists, for two days of first-class networking, discussions, exploration, and collaboration. The event will be held at the prestigious Louvre Palace, offering attendees an unforgettable experience with curated events, gourmet food, and networking among the world-class Web3 community on June 10-11, 2024.

The event will host over 2,500 attendees from across the globe looking for the latest innovations and trends in the Web3 world. Experts and participants will navigate the pivotal topics of technology, economics, and policies for a decentralized future. Proof Of Talk offers a robust forum for attendees to connect and exchange their fresh lease of ideas and theories through:

• 25+ panel discussions
• 15+ Workshops
• 5+ Firesides
• 3+ keynotes
• 2 stages

Eminent industry leaders will preside over speaker sessions, taking on crucial topics through intense discussions and interactions with an immersive audience of enthusiasts, start-ups, executives, and investors. The agenda includes topics like DeFi, TradFi, RWA, AI-Integration, cybersecurity, the Future of Bitcoin, Blockchain Interoperability, machine intelligence, and more.

Experts will also speak about how Web3 is impacting lifestyle through gaming, fashion, and sports modules. They will discuss the revolution in the world of gaming, its success metrics, and what the future holds for the World of gaming using Web3 technologies. Technology leaders will also share their invaluable insights on how traditional economic systems can be adapted to novel systems of finance, such as DeFi.

The conference has numerous great food and drink breaks, where attendees can also connect with industry leaders and peers for meaningful discussions and networking. The goal of the conference lies in using industry personas to shape the world of Web3.

To learn more, please visit https://ibn.fm/z1N2s

• The strategic venture marks a milestone in the company’s expansion into the energy sector, demonstrating GEMXX’s commitment to diversification and growth
• The project will be overseen by Dinesh Kumar Sarraf, the former chairman and managing director of Oil and Natural Gas Corporation Ltd, India’s leading exploration and production company
• The drilling of the four test wells is set to begin in the coming months, with expected results providing valuable data on the region’s oil potential

GEMXX (OTC: GEMZ), a publicly traded exploration company engaged in gold, gemstones, oil, and gas, has announced the signing of a Definitive Agreement with Latin Energy Partners (“LEP”) to drill four test wells in a promising geological formation in Latin America. This strategic venture represents a significant milestone in GEMXX’s expansion into the energy sector, highlighting the company’s dedication to diversification, growth, and enhancing shareholder value. For more information, visit (https://ibn.fm/wW3Jo).

Latin Energy Partners is a rising independent exploration and production company focused on discovering substantial hydrocarbon reserves in Latin America, an area with significant untapped potential. LEP leverages extensive intellectual property and deep regional geological knowledge in its operations. Aiming to become a key player in Latin America’s oil sector, Latin Energy Partners is dedicated to the sustainable and responsible development of natural resources, utilizing environmentally and socially conscious methods.

The project will be overseen by Dinesh Kumar Sarraf, the former chairman and managing director of Oil and Natural Gas Corporation Ltd (“ONGC”), India’s leading exploration and production company. During his tenure, Mr. Sarraf led numerous international ventures and managed assets exceeding $15 billion.

His vast experience and strategic insight are now guiding LEP in the identification and development of giant (500-million barrel) and super-giant (3-billion+ barrel) oil fields previously overlooked in Latin America. GEMXX believes Latin America is one of the last underdeveloped energy opportunities on Earth, quickly emerging due to demand and deregulation.

Richard Clowater, CEO of GEMXX, said the company was thrilled to collaborate with Latin Energy Partners and leverage Sarraf’s unparalleled expertise in the oil and gas industry. “This partnership aligns with our strategic goals of resource diversification and capitalizing on high-potential opportunities in the energy sector,” Clowater added. “The drilling of these test wells is a crucial step towards unlocking significant value for our shareholders.”

Mr. Sarraf leads a team of distinguished energy industry experts with decades of global oil and gas exploration experience. Their collective knowledge will be crucial for the project’s success, from initial drilling to potential full-scale production.

Mr. Sarraf said his team was excited to embark on this new venture with GEMXX Corporation. “The geological formation we are targeting holds substantial promise, and we are confident that our combined efforts will yield significant results. This project exemplifies the innovative and collaborative spirit needed to address the global energy demand,” he explained.

The drilling of the four test wells is set to begin in the coming months, with expected results providing valuable data on the region’s oil potential. GEMXX and LEP will continue to keep stakeholders informed as the project advances.

For more information, visit the company’s website at www.GEMXX.com.

NOTE TO INVESTORS: The latest news and updates relating to GEMZ are available in the company’s newsroom at https://ibn.fm/GEMZ

• ECGI is implementing several prudent measures to create a stronger foundation for pursuing new strategic ventures and growth opportunities
• The company recently announced an agreement to convert $2 million of debt into equity, with conversion expected to be completed during Q4 of its fiscal year
• ECGI has previously announced the reduction of over $1.5 million in liabilities, a reduction of over $350,000 in convertible notes payable and accrued interest, and an improvement in total stockholders’ deficit totaling over $1 million
• The company is determined to position itself to aggressively identify and capitalize on growth opportunities that align with its business objectives

ECGI Holdings (OTC: ECGI), a diversified holding company with a distinctive portfolio encompassing viticulture and luxury fashion, recently announced an agreement to convert $2 million of debt into equity. The agreement, anchored in section 3(a)(10) of the Securities Act of 1933, is a significant milestone in the company’s ongoing efforts to enhance financial stability in pursuit of significant market opportunities. The debt-to-equity conversion is set to be completed during the ECGI’s fiscal fourth quarter, ending August 31, 2024 (https://ibn.fm/kTWFt).

The 3(a)(10) debt-to-equity conversion is to strengthen the company’s balance sheet, alleviating a significant portion of its financial obligations, and allowing it to redirect its resources toward growth and innovation. During the first two quarters of fiscal 2024, ECGI implemented a number of strategies to reduce the strain of past debts.

The company recently reported successfully identifying and reducing over $1.5 million in accounts payable and accrued liabilities. ECGI heralded this achievement as a testament to its ongoing commitment to operational efficiency and fiscal responsibility. With the significant reduction in its liabilities and the ongoing cleanup of its balance sheet, a March 2024 news release said, the company anticipates a notably positive effect on its share structure.

In addition, ECGI identified and implemented the reduction of more than $350,000 in convertible notes payable and accrued. The company also reported an improvement in the total stockholders’ deficit, amounting to over $1 million. ECGI believes these recent measures to reduce liabilities will contribute significantly to long-term shareholder value as well as the company’s overall economic vitality.

“By reducing the strain of past debts, we are creating a firmer foundation for pursuing new strategic ventures and growth opportunities,” ECGI said in its news release announcing the debt-to-equity conversion. “We expect these financial maneuvers to bolster investor confidence and attract further investments, enhancing shareholder value and solidifying our market position.”

ECGI’s extended commitment to financial health, intended to help unlock future growth potential, is supported operationally by its ongoing focus on growth opportunities that align with its business opportunities. This focus has led to the company investing in Pacific Saddlery, Inc., a premier manufacturer and retailer of luxury products and services. Pacific Saddlery debuted a new mobile retail boutique at the prestigious Desert International Horse Park’s Desert Circuit event earlier this year. The mobile boutique concept enabled ECGI and Pacific Saddlery to take their luxury equestrian products closer to professionals and enthusiasts.

In addition to its strategic investment in Pacific Saddlery, ECGI owns and manages a five-acre vineyard in Lake County, California. The vineyard specializes in the cultivation of Petite Sirah, a variety of grapes famed for its bold and rich character. Besides aligning with the growing demand for unique and high-quality wine experiences, the vineyard enables ECGI to tap into the U.S. wine market, expected to grow from $60.1 billion in 2024 to $73.4 billion by 2028, according to Statista (https://ibn.fm/rA0a1).

ECGI is also eyeing the U.S. segment of the global short-term rental market. The global market is projected to grow at a CAGR of 10.87% from 2024 to 2033, reaching $315.18 billion by the end of the forecast period from $112.31 billion in 2023 (https://ibn.fm/bI0hr). To capitalize on this expected growth, ECGI is transforming its 40-acre Lake County, California, property into a luxurious short-term rental destination known as Vintner’s Caldera Ranch. The program was launched in early May (https://ibn.fm/mp9vO), and includes exposure in Airbnb, Vrbo, and Bookings.com. Evolve will continue to leverage its expertise in maximizing rental potential and delivering exceptional guest experiences to ensure that Vintner’s Caldera Ranch exceeds the high standards of service and luxury that guests expect.

For more information, visit the company’s website at www.ECGIHoldings.com.

NOTE TO INVESTORS: The latest news and updates relating to ECGI are available in the company’s newsroom at https://ibn.fm/ECGI

• Emperor Metals’ 8,000 m drill program will focus on the open pit concept revealed during last year’s program
• Both high-grade resources of 5.8 g/t Au over 10.85 m and lower-grade bulk tonnage of 1.69 g/t Au over 25 m were intercepted in 2023
• The company intends to continue leveraging its advanced artificial intelligence models to guide targeting efforts for the upcoming drill season
• The Duquesne West Gold Property  hosts a historical inferred mineral resource estimate of 727,000 ounces of gold at a grade of 5.42 g/t and an average thickness of 5.71 meters in 4.171 million tonnes* (see note at bottom)

Emperor Metals (CSE: AUOZ) (OTCQB: EMAUF) (FRA: 9NH), an advanced stage gold exploration company, has officially resumed drilling at its flagship Duquesne West Gold Property, located within the historic Duparquet gold mining camp in the Superior Province’s southern part of the Abitibi Greenstone Belt of Rouyn-Noranda, Quebec. The 8,000 m drill program at the Duquesne West Gold Project follows up on the company’s initial drill campaign in 2023, which revealed a significant open pit concept above a high-grade gold deposit (https://ibn.fm/mXzJf).

The property hosts an estimated historical mineral resource of 727,000 ounces of gold at a grade of 5.42 g/t Au. Emperor Metals has leveraged artificial intelligence and machine learning to create a reinterpretation of the existing geological model and highlight the opportunity for additional discovery of ounces by revealing previously unknown gold trends.

According to Emperor Metals CEO John Florek, the Phase II drilling program gives the company the ability to add ounces more rapidly on the project, as a result of its capability to add potentially open pitable mineralization above the existing high-grade historical resource. The company’s entire 2024 exploration program will predominantly concentrate on the open pit concept, leveraging insights obtained in 2023 and its advanced AI models to determine drilling targets.

In 2023, the company used AI to create the first 3D geological and mineralized model to guide a highly successful drilling campaign of 8,579 m. During this campaign, Emperor extended high-grade zones laterally by intercepting grades of 15.8 g/t Au over 10.85 m, but also intercepted lower grade bulk tonnage of 1.69 g/t Au over 25 m. These results are what prompted the development of a different exploration strategy, based on the potential existence of an open pit overlying the high-grade deposit.

Emperor’s 2024 strategy is thus aimed at continuing to improve the open-pit economics by expanding ounces in four key ways:

• Expanding ounces internally and externally to open-pit shells
• Expanding the footprint of high-grade lenses inside and outside open-pit shells
• Determining lower-grade bulk-tonnage incremental ounces in host rocks
• Continuing to build quality ounces internally and externally

In addition to the 8,000 m drilling program at Duquesne West, the company has also begun sampling near-surface core from the historical core library that was not assayed by previous explorers. Up to 70% of this core has not been assayed within the open-pit conceptual model. Emperor plans 8,000 additional meters of core sampling from the historic core library for this program.

By resuming drilling at its Duquesne West Gold Property, the company is reconfirming its commitment to expanding its resource base and enhancing shareholder value. Showcasing its strategic vision and operational capabilities, Emperor Metals is well-positioned to advance its exploration projects and continue to reinforce its standing as a dynamic player in the gold exploration industry.

“Emperor is well funded with approximately $4 million in working capital and will advance the Duquesne West Project towards an updated mineral resource,” Florek added. “Gold prices continue to show strength, and we are confident that everything is now in place to give our shareholders the best chance of a successful upside on this project.”

*Power-Fardy and Breede, 2011. The Mineral Resource Estimate (“MRE”) constructed in 2011 is considered historical in nature as it was constructed prior to the most recent Canadian Institute of Mining and Metallurgy (“CIM”) standards (2014) and guidelines (2019) for mineral resources. In addition, the economic factors used to demonstrate reasonable prospects of eventual economic extraction for the MRE have changed since 2011. A qualified person has not done sufficient work to consider the MRE as current. Emperor is not treating the historical MRE as current. The reader is cautioned not to treat it, or any part of it, as a current MRE.

For more information, visit the company’s website at www.EmperorMetals.com.

NOTE TO INVESTORS: The latest news and updates relating to EMAUF are available in the company’s newsroom at https://ibn.fm/EMAUF

• CARB certification is awarded to vehicle manufacturers that meet specific emissions standards in compliance with CARB regulations
• CARB is charged with protecting public from harmful effects of air pollution, developing programs and actions to fight climate change
• “Having both our Class 1 and Class 3 commercial EVs now CARB and EPA certified will continue to drive sales in all states across America,” says Mullen CEO

With environmental concerns becoming an increasing priority, more states, companies, and consumers are paying attention to — and prioritizing — environmentally friendly products and practices. Mullen Automotive (NASDAQ: MULN), an emerging EV manufacturer, shares this commitment to being environmentally responsible. To underscore this commitment, the company announced that its Mullen THREE, an all-electric Class 3 low cab forward chassis truck, has received certification from the California Air Resources Board (“CARB”) (https://ibn.fm/PqLr8).

According to the company, the certification is awarded to vehicle manufacturers that meet specific emissions standards in compliance with CARB regulations. The District of Columbia and 14 states, including California, have adopted vehicle standards that require additional approvals beyond EPA regulations.

In the announcement, Mullen noted that both its Class 1 and Class 3 commercial vehicles are Environmental Protection Agency (“EPA”) and CARB certified. In addition, both vehicles are in full compliance with U.S. Federal Motor Vehicle Safety Standards. With these certifications secured, the Mullen ONE EV van and Mullen THREE EV truck can be sold anywhere in the United States.

“CARB is charged with protecting the public from the harmful effects of air pollution and developing programs and actions to fight climate change,” the California Air Resources Board website explains. “From requirements for clean cars and fuels to adopting innovative solutions to reduce greenhouse gas emissions, California has pioneered a range of effective approaches that have set the standard for effective air and climate programs for the nation, and the world.

“CARB’s mission is to promote and protect public health, welfare, and ecological resources through effective reduction of air pollutants while recognizing and considering effects on the economy,” the website continues. “CARB is the lead agency for climate change programs and oversees all air pollution control efforts in California to attain and maintain health-based air quality standards.”

Gaining CARB certification means that the Mullen THREE EV truck is eligible for important state incentive programs, including involvement with California’s HVIP project, which offers a rebate of up to $45,000. When combined with the federal tax credit of $7,500, the cost for the Mullen THREE, which has a suggested MSRP of $68,500, could be less than $20,000.

“CARB approval accelerates commercialization of the Mullen THREE and makes our vehicle even more appealing to customers who want to electrify their fleets,” said David Michery, CEO and chairman of Mullen Automotive. “Having both our Class 1 and Class 3 commercial EVs now CARB and EPA certified will continue to drive sales in all states across America.”

Mullen Automotive (NASDAQ: MULN) is a Southern California–based automotive company building the next generation of commercial electric vehicles (“EVs”) with two United States–based vehicle plants located in Tunica, Mississippi, (120,000 square feet) and Mishawaka, Indiana (650,000 square feet). In August 2023, Mullen began commercial vehicle production in Tunica. In September 2023, Mullen received IRS approval for federal EV tax credits on its commercial vehicles with a Qualified Manufacturer designation that offers eligible customers up to $7,500 per vehicle. As of January 2024, both the Mullen ONE, a Class 1 EV cargo van, and Mullen THREE, a Class 3 EV cab chassis truck, are California Air Resource Board (“CARB”) and EPA certified and available for sale in the U.S. Recently CARB issued HVIP approval on the Mullen THREE, Class 3 EV truck, providing a cash voucher of up to $45,000 at the time of vehicle purchase. The company has also recently expanded its commercial dealer network with the addition of Pritchard EV, National Auto Fleet Group, Ziegler Truck Group, and Range Truck Group, providing sales and service coverage in key Midwest, West Coast, and Pacific Northwest markets. The company also recently announced Foreign Trade Zone (“FTZ”) status approval for its Tunica, Mississippi, commercial vehicle manufacturing center. FTZ approval provides a number of benefits, including deferment of duties owed and elimination of duties on exported vehicles.

For more information about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

Recent Achievements

• Annovis Bio recently announced statistically significant data from its Phase II/III Alzheimer’s study, showcasing Buntanetap’s potential to improve cognition in patients with mild AD
• Annovis Bio recently announced last patient last visit in the Phase III study of Buntanetap in patients with early Parkinson’s disease and expects data announcement in June 2024, marking significant progress in expanding its therapeutic reach
• The company has solidified strategic partnerships to enhance its research capabilities and broaden its market reach

Investment Considerations

• Unique Market Position: Annovis Bio is the only company developing a drug for both AD and PD that inhibits multiple neurotoxic proteins
• Strong Clinical Results: Buntanetap’s Phase II/III data shows significant cognitive improvement in early AD patients
• Strategic Growth Plans: Upcoming Phase III trials and strong patent protections position Annovis Bio for long-term success
• Significant Market Need: With the growing prevalence of neurodegenerative diseases, the demand for effective treatments is substantial

Annovis Bio (NYSE: ANVS) is a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (“AD”) and Parkinson’s Disease (“PD”). Annovis Bio stands out by developing a drug that targets multiple neurotoxic proteins simultaneously, aiming to restore axonal and synaptic activity. This innovative approach aims to treat memory loss and dementia associated with AD and body and brain dysfunction associated with PD, making Annovis a unique player in the neurodegeneration space.

Lead Drug Candidate: Buntanetap

Buntanetap (formerly Posiphen) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. This multifaceted inhibition improves synaptic transmission and axonal transport, reduces neuroinflammation, and protects nerve cells from dying. Unlike monoclonal antibody therapies, Buntanetap is an orally available small molecule capable of inhibiting multiple neurotoxic proteins at once, positioning it as a comprehensive solution for neurodegenerative diseases.

In a recent Phase II/III Alzheimer’s study, Buntanetap demonstrated statistically significant efficacy. Patients with early AD showed a significantly higher rate of improvement in ADAS-Cog 11 scores across all treatment doses compared to placebo, with a -3.3 point improvement compared to -0.3 for placebo (p < 0.01). Plasma Tau protein levels also reduced, consistent with previous Phase II biomarker data, further validating Buntanetap’s mechanism of action.

Similarly, in the Phase III study of Buntanetap in patients with early Parkinson’s disease, significant advancements were observed. Topline data results are anticipated in June 2024. Preliminary findings indicate promising results in improving cognitive and motor function, underscoring Buntanetap’s potential as a transformative therapy for Parkinson’s disease.

Market Opportunity

The aging population presents a significant market opportunity, with nearly 7 million Americans currently suffering from Alzheimer’s Disease (“AD”), a figure projected to rise to almost 13 million by 2050 (Alzheimer’s Association) (Republican Policy Committee). Additionally, approximately 1.2 million people in the U.S. have Parkinson’s Disease (SingleCare).

The economic burden of Alzheimer’s is immense, with care costs expected to reach $360 billion in 2024 and escalate to nearly $1 trillion annually by 2050. The need for effective, comprehensive treatments like Buntanetap is more critical than ever.

Company Highlights

• Innovative Therapeutic Approach: Annovis Bio uniquely targets multiple neurotoxic proteins, aiming to restore nerve cell health and improve cognitive and motor function in AD and PD patients
• Robust Clinical Data: Phase II/III studies show significant improvements in cognitive function and biomarker levels in early AD patients
• Groundbreaking Clinical Insights: Preliminary results from Phase II studies indicate significant improvements in motor functions and speed in patients with Parkinson’s Disease (“PD”)
• Upcoming Phase III Trials: Plans are underway for an 18-month Phase III trial focusing on biomarker-positive early AD patients, designed to further validate Buntanetap’s disease-modifying potential
• Capital Efficiency: Annovis Bio is capital-efficient, with zero debt and multiple global patents extending into the 2040s

Management Team

Maria L. Maccecchini, Ph.D., Founder, President, CEO, and Executive Board Member, founded Annovis Bio in May 2008 with the mission to develop better therapeutics for Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. She has previously been a partner and director at two angel groups, Robin Hood Ventures and MidAtlantic Angel Group, and founded Symphony Pharmaceuticals/Annovis, which was sold to Transgenomic in 2001. Her extensive experience includes roles such as General Manager at Bachem Bioscience and Head of Molecular Biology at Mallinckrodt. Dr. Maccecchini holds a Ph.D. in biochemistry from the Biocenter of Basel, with postdoctoral work at Caltech and the Roche Institute of Immunology.

Cheng Fang, Ph.D., Senior VP of Research and Development, is an accomplished neuroscientist with two decades of experience in neurodegenerative diseases. She has a successful track record of scientific publications and contributions, coupled with extensive pre-clinical and clinical development experience. Dr. Fang has been instrumental in advancing the understanding of neurodegenerative disease mechanisms and developing therapeutic strategies.

Michael Christie, Ph.D., VP of Process Chemistry, has over 40 years of experience in the pharmaceutical industry, focusing on process chemistry R&D, pilot plant production, and GMP operations. He has held senior management positions at companies such as SmithKline, Rhodia, Teva, and Cephalon, and founded a contract process R&D service company, which was later acquired by ChiRex. Dr. Christie is co-author or co-inventor on several publications and patents. He earned his BS in chemistry from the University of Michigan and his doctorate from MIT.

Melissa Gaines, Senior VP of Clinical Operations, is an accomplished clinical research professional with over 20 years of experience across academia, contract research organizations, and pharmaceutical companies. She has proven abilities in monitoring and managing Phase I to IV clinical trials, specializing in CNS disorders and extending to a broad range of therapeutic indications. Her CNS experience spans from small Phase I and II studies to large global Phase III trials in Alzheimer’s disease, Parkinson’s disease, sleep disorders, and various psychiatric diseases in both adult and pediatric populations. In her current role, she oversees and supports all clinical project activities, driving operational success and ensuring high-quality clinical outcomes.

Learn more about the Annovis Bio team on LinkedIn.

For more information, visit the company’s website at www.AnnovisBio.com.

NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS

Aspermont, a leading media services provider, in partnership with Rule Investment Media, is organizing the Mining News Select Perth, coming up June 17-18, 2024 in Pan Pacific Perth. The event focuses on providing resources, connections, and higher ROI, to global resource companies in the minerals and gold sector.

Aspermont caters to the global resource industries. With over 20+ years of creating a commercial model for B2B media, Aspermont offers high-value content through its research, publication, and events to global resource industries.

The team at Miningnews.net has launched the MiningNews Select event to offer the Australian mining sector and capital-raising markets a robust platform for education, networking, and collaboration. The research team curates a list of crucial miners and companies selected based on 13 weighted metrics. They present rated development projects to an audience of seasoned institutional and retail investors.

Mining resource companies can connect and gain important insights into key industry drivers and investment opportunities. Investors can discover promising mining companies and explore potential avenues for investment. The event will feature over 250 focused and educated private and institutional investors, 400+ investor meetings, and speaker sessions presided over by an impressive lineup of leading industry dignitaries. There are more than 30 junior companies with exceptional development projects.

MiningNews Select puts up branded booths with screens and seating where mining companies can conduct investor meetings. A panel of experts will conduct the meetings and one-to-one discussions between investors and companies.

The team at MiningNews Select has arranged for a concierge of more than 10 people to organize and deliver investor meetings, and offers productive outcomes through networking where valuable connections are forged and collaborative deals are sealed. Mining companies from across Australia connect with industry leaders and get a range of follow-ups after the show.

To learn more, please visit https://ibn.fm/mei0i

• American-based SenesTech, rodent fertility control product provider, growing rapidly with its highly successful and unmatched rodent control technology, is now expanding from government and business markets to the direct consumer market with the launch of its dedicated online store on Amazon
• This brings SenesTech and its products closer to consumers in what its management notes will help drive growth in its fertility solutions for many years to come, and carving out a significant market share in an industry that currently posts over $1 billion in sales annually
• Amazon’s addition follows SenesTech’s recent multiple overseas distribution deals which opened it up to Europe, New Zealand, Australia, and Singapore

SenesTech (NASDAQ: SNES), a rodent fertility control product provider and the inventor of the only EPA-registered contraceptive for male and female rats, just announced the launch of its dedicated online store on Amazon. As the world’s largest online retailer, this move brings SenesTech and its products closer to consumers, marking a significant step forward in distributing its flagship Evolve(TM) soft bait (https://ibn.fm/cJrCf). 

According to Joel Fruendt, the company’s CEO, this launch positions SenesTech to revolutionize how everyday consumers safely and proactively combat rodent pests, particularly when regulations are putting more restrictions on applying commonly used poisons. It also marks a significant milestone for the company, notably since Evolve(TM) was only launched earlier in the year.

“Evolve has already garnered acclaim in the professional market since its launch at the beginning of the year,” noted Mr. Fruendt. “Now, it’s poised to revolutionize how everyday consumers can safely and proactively combat rodent pests with its availability on Amazon,” he added.

SenesTech announced multiple global distribution deals in March, opening it up to various markets, including Europe, New Zealand, Australia, and Singapore. While making the announcement, SenesTech’s management shared their optimism about these deals, citing how they would be integral in setting the company up for more success in the 2024 calendar year. The addition of the dedicated online Amazon store points to the company’s commitment to further pushing its products and ultimately carving out a significant market share in an industry that currently posts sales of over $1 billion annually.

Various studies have pointed to the overall efficiency of SenesTech’s offering. They have shown that with its contraceptives, rodent populations can be reduced by half in just six months and over 90 percent in one year. This is significant, especially given that two rats, given sufficient food, water, and harborage, will produce 15,000 offspring within a year. With the growing regulations on using poisons to control rodent populations, SenesTech is taking a more proactive approach, offering a safe, effective, and convenient alternative to traditional poison-heavy pest control.

Since its launch, Evolve’s uptake has been impressive for SenesTech. It speaks to its overall effectiveness and a glaring market gap that the company is satisfying with its superior range of products. The launch of the Amazon store now brings the products closer to customers, a move set to drive up sales and the overall adoption of the company’s products. According to Mr. Fruendt, this move is expected to drive continued growth in the company’s revolutionary fertility soft bait solutions for many years to come.

For more information, visit the company’s website at www.SenesTech.com.

NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES